In short, dual inhibition of BRAF and MEK to unresectable or metastatic melanoma with BRAF V600 mutation is superior to inhibiting BRAF or MEK separately in the form of ORR, PFS, OS, and quality of life. This evidence concerns the gene BRAF and metastatic melanoma.